Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells
Journal for ImmunoTherapy of Cancer · 2023
DOI: 10.1136/jitc-2022-006381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Sheng Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Natural Medicinal Chemistry, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangdong Basic and Applied Basic Research Foundation, Local Innovative and Research Teams Project of the Guangdong Pearl River Talents Program, Science and Technology Projects in Guangzhou.
Abstract (Originalsprache)
Background
Advanced or metastatic prostate cancer (PCa) is still an incurable malignancy with high lethality and a poor prognosis. Despite the remarkable success of immunotherapy against many types of cancer, most patients with PCa receive minimal benefit from current immunotherapeutic strategies, because PCa is an immune cold tumor with scarce T-cell infiltration in the tumor microenvironment. The aim of this study was to develop an effective immunotherapeutic approach for immune cold PCa tumors.
Methods
The therapeutic efficacy of androgen deprivation therapy (ADT) and zoledronic acid (ZA) plus thymosin α1 (Tα1) therapy was analyzed retrospectively in patients with advanced or metastatic PCa. The effects and mechanisms by which ZA and Tα1 regulated the immune functions of PCa cells and immune cells were evaluated by a PCa allograft mouse model, flow cytometric analysis, immunohistochemical and immunofluorescence staining assays, and PCR, ELISA, and Western blot analyses.
Results
In this study, clinical retrospective analysis revealed that ADT combined with ZA plus Tα1 improved the therapeutic outcomes of patients with PCa, which might be associated with an enhanced frequency of T cells. ZA and Tα1 treatment synergistically inhibited the growth of androgen-independent PCa allograft tumors, with increased infiltration of tumor-specific cytotoxic CD8 + T cells and enhanced tumor inflammation. Functionally, ZA and Tα1 treatment relieved immunosuppression in PCa cells, stimulated pro-inflammatory macrophages, and enhanced the cytotoxic function of T cells. Mechanistically, ZA plus Tα1 therapy blocked the MyD88/NF-κB pathway in PCa cells but activated this signaling in macrophages and T cells, altering the tumor immune landscape to suppress PCa progression.
Conclusions
These findings uncover a previously undefined role for ZA and Tα1 in inhibiting the disease progression of immune cold PCa tumors by enhancing antitumor immunity and pave the way for the application of ZA plus Tα1 therapy as an immunotherapeutic strategy for treating patients with immunologically unresponsive PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Natural Medicinal Chemistry, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, Guangdong, China.
- Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, Guangdong, China.
- Research Center of Cancer Diagnosis and Therapy, Department of Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
- The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
- Department of Natural Medicinal Chemistry, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China dmzhang701@jnu.edu.cn zhaojianfu@jnu.edu.cn chywc@aliyun.com.
ORCID-Profile: Dongmei Zhang
Förderung
- Guangdong Basic and Applied Basic Research Foundation
- Local Innovative and Research Teams Project of the Guangdong Pearl River Talents Program
- Science and Technology Projects in Guangzhou
- National High-level Personnel of Special Support Program
- Natural Science Foundation of Guangdong Province
- China Postdoctoral Science Foundation
- Key-Area Research and Development Program of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Wang, S., Huang, M., Chen, M., Sun, Z., Jiao, Y., Ye, G., Pan, J., Ye, W., Zhao, J., & Zhang, D. (2023). Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-006381
Vancouver
Wang S, Huang M, Chen M, Sun Z, Jiao Y, Ye G, et al. Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2022-006381
BibTeX
@article{Wang2023,
author = {Wang, Sheng and Huang, Maohua and Chen, Minfeng and Sun, Zhiting and Jiao, Yubo and Ye, Geni and Pan, Jinghua and Ye, Wencai and Zhao, Jianfu and Zhang, Dongmei},
title = {Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
doi = {10.1136/jitc-2022-006381}
}
EUVIMED